Meeting
2016 Genitourinary Cancers Symposium
A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
Authors
Karen A. Autio
Memorial Sloan Kettering Cancer Center, New York, NY
Karen A. Autio , Jorge A. Garcia , Ajjai Shivaram Alva , Lowell L. Hart , Matthew I. Milowsky , Edwin M. Posadas , Charles J. Ryan , Jason Mark Summa , Hagop Youssoufian , Howard I. Scher , Robert Dreicer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01812746
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 233)
DOI
10.1200/jco.2016.34.2_suppl.233
Abstract #
233
Poster Bd #
K4
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Peter Petrylak
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2023 ASCO Genitourinary Cancers Symposium
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
First Author: Simon J. Crabb
Poster
2022 ASCO Annual Meeting
A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Ulka N. Vaishampayan